Transcriptome Profiling Identifies HMGA2 as a Biomarker of Melanoma Progression and Prognosis
Raskin L, Fullen D, Giordano T, Thomas D, Frohm M, B. K, Ahn J, Mukherjee B, Johnson T, Gruber S. Transcriptome Profiling Identifies HMGA2 as a Biomarker of Melanoma Progression and Prognosis. Journal Of Investigative Dermatology 2013, 133: 2585-2592. PMID: 23633021, PMCID: PMC4267221, DOI: 10.1038/jid.2013.197.Peer-Reviewed Original ResearchConceptsAmerican Joint Committee on CancerOverall survivalTissue microarrayPrimary melanomaMelanoma pathogenesisMelanoma progressionAssociated with disease-free survivalAnalysis of tissue microarraysMetastases-free survivalDisease-free survivalHMGA2 overexpressionCox proportional hazards regression modelsLog-rank testPredictors of survivalProportional hazards regression modelsHazards regression modelsBRAF/NRAS mutationsPrimary tumorPrognostic featuresMelanoma metastasesClinicopathological characteristicsReal-time PCRGenetic alterationsAQUA analysisMelanoma development